首页> 外文期刊>Hepato-gastroenterology. >Primary Results of Salvage Liver Transplantation in the Patients with Unresectable Recurrent Hepatocellular Carcinoma after Initial Liver Resection
【24h】

Primary Results of Salvage Liver Transplantation in the Patients with Unresectable Recurrent Hepatocellular Carcinoma after Initial Liver Resection

机译:肝切除术后不可切除的复发性肝细胞癌患者挽救肝脏移植的主要结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aims: Salvage liver transplantation (SLT) is a treatment choice for recurrent HCC fulfilling the Milan criteria. However, there is no consensus on the value of SLT for recurrent HCC beyond the Milan criteria, especially for unresectable HCC. Methodology: Eleven patients with recurrent HCC underwent SLT in Tongji ospital between January 2003 and July 2010. All the 1 patients were considered unresectable because of deteriorated liver function, multiple bilobar tumors or vascular invasion. The outcomes and prognostic factors;of these patients were analyzed. Results: At a median follow up of 30 months, six patients were alive. Four patients died from HCC recurrence, and one died from gastric cancer. survival rates after SLT were 58.4%, 72.3% and 86.1% respectively and 90.9%, 40.6% and 40.6%, respectively Vascular invasion, recurrent HCC beyond the Milan cri;teria and early recurrence within 18 months after initial resection were negative prognostic factors of SLT for' recurrent HCC. Conclusions: SLT can be recommended as an alternative treatment for recurrent HCC fulfilling the Milan criteria. For those beyond the Milan criteria or with vascular invasion, or early recurrence after initial resection, however, SLT is not beneficial and should not be recommended.
机译:背景/目的:挽救性肝移植(SLT)是复发性HCC符合米兰标准的治疗选择。但是,对于超出米兰标准的复发性肝癌,特别是不可切除的肝癌,SLT的价值尚无共识。方法:2003年1月至2010年7月间,11例HCC复发患者在同济地区进行了SLT。由于肝功能恶化,多发性双叶肿瘤或血管侵犯,所有1例患者均被认为无法切除。分析了这些患者的结果和预后因素。结果:中位随访30个月,有6名患者还活着。 4例患者死于HCC复发,1例死于胃癌。 SLT后的生存率分别为58.4%,72.3%和86.1%,90.9%,40.6%和40.6%,分别是血管侵犯,米兰标准以外的复发性HCC和初次切除后18个月内早期复发是预后的阴性预后因素。 SLT用于复发性HCC。结论:对于符合米兰标准的复发性肝癌,推荐使用SLT作为替代治疗。对于超出米兰标准或有血管侵犯或初次切除后早期复发的患者,SLT不利,因此不建议使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号